The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems
Open accessAbstract
Targeting nanoparticle (NP) carriers to sites of disease is critical for their successful use as drug delivery systems. Along with optimization of physicochemical properties, researchers have focused on surface modification of NPs with biological ligands. Such ligands can bind specific receptors on the surface of target cells. Furthermore, biological ligands can facilitate uptake of modified NPs, which is referred to as ‘active targeting’ of NPs. In this review, we discuss recent applications of biological ligands including proteins, polysaccharides, aptamers, peptides, and small molecules for NP-mediated drug delivery. We prioritized studies that have demonstrated targeting in animals over in vitro studies. We expect that this review will assist biomedical researchers working with NPs for drug delivery and imaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“Commercialized formulations such as Doxil and Abraxane are excellent examples of NP drug delivery systems that have improved therapy in patients [2,3].”
BackgroundStrategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
CD44 is the principal cell surface receptor for hyaluronate
Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B., & Seed, B. (1990) · Cell · doi:10.1016/0092-8674(90)90694-a · Cited by 2,438
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Active targeting schemes for nanoparticle systems in cancer therapeutics
Byrne, J. D., Betancourt, T., & Brannon-Peppas, L. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.08.005 · Cited by 1,731
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
van Dam, G. M., Themelis, G., Crane, L. M. A., Harlaar, N. J., Pleijhuis, R. G., Kelder, W., Sarantopoulos, A., de Jong, J. S., Arts, H. J. G., van der Zee, A. G. J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2472 · Cited by 1,545
Nanoparticle-based theranostic agents
Xie, J., Lee, S., & Chen, X. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.009 · Cited by 1,422
Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities
Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. (2012) · Science · doi:10.1126/science.1226338 · Cited by 1,322
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010) · Science · doi:10.1126/science.1183057 · Cited by 1,075
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
Teesalu, T., Sugahara, K. N., Kotamraju, V. R., & Ruoslahti, E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908201106 · Cited by 812 · cited 1×
“Interestingly, when the iRGD peptide is cleaved by proteases in tumor cells, it produces a CRGDK/R derivative peptide that has diminished affinity for αv integrin but increased affinity for neuropilin-1 (NRP-1) [30].”
BackgroundBartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 803
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles
Choi, C. H. J., Alabi, C. A., Webster, P., & Davis, M. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914140107 · Cited by 699
In Vivo Targeted Delivery of Nanoparticles for Theranosis
Koo, H., Huh, M. S., Sun, I.-C., Yuk, S. H., Choi, K., Kim, K., & Kwon, I. C. (2011) · Accounts of Chemical Research · doi:10.1021/ar2000138 · Cited by 447
Self-citationExploring the Role of RGD-Recognizing Integrins in Cancer
Nieberler, M., Reuning, U., Reichart, F., Notni, J., Wester, H.-J., Schwaiger, M., Weinmüller, M., Räder, A., Steiger, K., & Kessler, H. (2017) · Cancers · doi:10.3390/cancers9090116 · Cited by 429
Muhamad, N., Plengsuriyakarn, T., & Na-Bangchang, K. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s165210 · Cited by 410
Cloaking nanoparticles with protein corona shield for targeted drug delivery.
Oh, J. Y., Kim, H. S., Palanikumar, L., Go, E. M., Jana, B., Park, S. A., Kim, H. Y., Kim, K., Seo, J. K., Kwak, S. K., et al. (2018) · Nature communications · doi:10.1038/s41467-018-06979-4 · Cited by 409 · cited 1×
“successfully used Afbs for active targeting of NPs [20].”
MethodSmart Nanocarrier Based on PEGylated Hyaluronic Acid for Cancer Therapy
Choi, K. Y., Yoon, H. Y., Kim, J.-H., Bae, S. M., Park, R.-W., Kang, Y. M., Kim, I.-S., Kwon, I. C., Choi, K., Jeong, S. Y., et al. (2011) · ACS Nano · doi:10.1021/nn202070n · Cited by 399
Multivalent Effects of RGD Peptides Obtained by Nanoparticle Display
Montet, X., Funovics, M., Montet-Abou, K., Weissleder, R., & Josephson, L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060515m · Cited by 388
Phenylboronic Acid-Installed Polymeric Micelles for Targeting Sialylated Epitopes in Solid Tumors
Deshayes, S., Cabral, H., Ishii, T., Miura, Y., Kobayashi, S., Yamashita, T., Matsumoto, A., Miyahara, Y., Nishiyama, N., & Kataoka, K. (2013) · Journal of the American Chemical Society · doi:10.1021/ja406406h · Cited by 348
Clark, A. J., & Davis, M. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517048112 · Cited by 280
Photoswitched Cell Adhesion on Surfaces with RGD Peptides
Auernheimer, J., Dahmen, C., Hersel, U., Bausch, A., & Kessler, H. (2005) · Journal of the American Chemical Society · doi:10.1021/ja053648q · Cited by 226
Target-specific delivery of peptide-based probes for PET imaging
Chen, K., & Conti, P. S. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.004 · Cited by 190
Aptamer–nanoparticle complexes as powerful diagnostic and therapeutic tools
Jo, H., & Ban, C. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.44 · Cited by 188
Understanding the Effects of Nanocapsular Mechanical Property on Passive and Active Tumor Targeting
Hui, Y., Wibowo, D., Liu, Y., Ran, R., Wang, H.-F., Seth, A., Middelberg, A. P. J., & Zhao, C.-X. (2018) · ACS Nano · doi:10.1021/acsnano.8b00242 · Cited by 186
Targeted cancer therapy through antibody fragments-decorated nanomedicines
Alibakhshi, A., Abarghooi Kahaki, F., Ahangarzadeh, S., Yaghoobi, H., Yarian, F., Arezumand, R., Ranjbari, J., Mokhtarzadeh, A., & de la Guardia, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.036 · Cited by 181
Novel strategies for the formulation and processing of poorly water-soluble drugs
Göke, K., Lorenz, T., Repanas, A., Schneider, F., Steiner, D., Baumann, K., Bunjes, H., Dietzel, A. H., Finke, J. H., Glasmacher, B., et al. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.05.008 · Cited by 172
Folate-targeted nanoparticles for rheumatoid arthritis therapy
Nogueira, E., Gomes, A. C., Preto, A., & Cavaco-Paulo, A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.12.365 · Cited by 161
Huo, M., Zhao, Y., Satterlee, A., Wang, Y., Xu, Y., & Huang, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.013 · Cited by 159
He, X., Chen, X., Liu, L., Zhang, Y., Lü, Y., Zhang, Y., Chen, Q., Ruan, C., Guo, Q., Li, C., et al. (2018) · Advanced Science · doi:10.1002/advs.201701070 · Cited by 117
Na, J. H., Lee, S. Y., Lee, S., Koo, H., Min, K. H., Jeong, S. Y., Yuk, S. H., Kim, K., & Kwon, I. C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.028 · Cited by 102
Self-citationReuter, K. G., Perry, J. L., Kim, D., Luft, J. C., Liu, R., & DeSimone, J. M. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b01362 · Cited by 101
Smith, B. J., Lyakhov, I. G., Loomis, K. H., Needle, D., Baxa, U., Yavlovich, A., Capala, J., Blumenthal, R. P., & Puri, A. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.04.005 · Cited by 99
Schieber, C., Bestetti, A., Lim, J. P., Ryan, A. D., Nguyen, T., Eldridge, R., White, A. R., Gleeson, P. A., Donnelly, P. S., Williams, S. J., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201202876 · Cited by 94
Yue, X., Zhang, Q., & Dai, Z. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.007 · Cited by 94
Roncato, F., Rruga, F., Porcù, E., Casarin, E., Ronca, R., Maccarinelli, F., Realdon, N., Basso, G., Alon, R., Viola, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06602-6 · Cited by 86
Fitzgerald, K. A., Malhotra, M., Gooding, M., Sallas, F., Evans, J. C., Darcy, R., & O’Driscoll, C. M. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.12.055 · Cited by 83
Lv, Y., Cao, Y., Li, P., Liu, J., Chen, H., Hu, W., & Zhang, L. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700354 · Cited by 83
Folate-modified PLGA nanoparticles for tumor-targeted delivery of pheophorbide a in vivo
Son, J., Yang, S. M., Yi, G., Roh, Y. J., Park, H., Park, J. M., Choi, M., & Koo, H. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.013 · Cited by 81
Self-citationRan, R., Wang, H., Liu, Y., Hui, Y., Sun, Q., Seth, A., Wibowo, D., Chen, D., & Zhao, C. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.017 · Cited by 75
Synergetic Combinations of Dual‐Targeting Ligands for Enhanced In Vitro and In Vivo Tumor Targeting
Liu, Y., Hui, Y., Ran, R., Yang, G., Wibowo, D., Wang, H., Middelberg, A. P. J., & Zhao, C. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800106 · Cited by 68
Duo, Y., Yang, M., Du, Z., Feng, C.-H., Chen, X., Wu, Y., Xie, Z., Zhang, F., Huang, L., Zeng, X., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.08.035 · Cited by 63
Lu, Z., Long, Y., Cun, X., Wang, X., Li, J., Mei, L., Yang, Y., Li, M., Zhang, Z., & He, Q. S. (2018) · Nanoscale · doi:10.1039/c8nr01184b · Cited by 56
Chi, L., Na, M., Jung, H.-K., Vadevoo, S. M. P., Kim, C.-W., Padmanaban, G., Park, T.-I., Park, J., Hwang, I., Park, K. U., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.260 · Cited by 54
Kim, K. S., Kim, J., Kim, D. H., Hwang, H. S., & Na, K. (2018) · Biomaterials Science · doi:10.1039/c7bm01084b · Cited by 44
Targeting Nanocarriers with Anisamide: Fact or Artifact?
Dasargyri, A., Kümin, C. D., & Leroux, J. (2016) · Advanced Materials · doi:10.1002/adma.201603451 · Cited by 43
Anselmo, A. C., Prabhakarpandian, B., Pant, K., & Mitragotri, S. (2017) · Translational Materials Research · doi:10.1088/2053-1613/aa5468 · Cited by 36
Dasargyri, A., Hervella, P., Christiansen, A. J., Proulx, S. T., Detmar, M. J., & Leroux, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.021 · Cited by 30
Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD
Фадеев, Р. С., Chekanov, A. V., Solovieva, M. E., Si, B., Nemtsova, E. R., Dolgikh, N., Fadeeva, I. S., Сенотов, А. С., Kobyakova, M. I., Evstratova, Y., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030525 · Cited by 27
Cited by
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization
Sanità, G., Carrese, B., & Lamberti, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587012 · Cited by 765
Harish, V., Tewari, D., Gaur, M., Yadav, A. B., Swaroop, S., Bechelany, M., & Barhoum, A. (2022) · Nanomaterials · doi:10.3390/nano12030457 · Cited by 623
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery
Spada, A., Emami, J., Tuszynski, J. A., & Lavasanifar, A. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00046 · Cited by 591
Metadata
- Authors
- Yoo, J., Park, C., Yi, G., Lee, D., & Koo, H.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-05-08
- Volume
- 11
- Issue
- 5
- Pages
- 640
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2944249153
- Cited by
- 726
- References
- 50
- FWCI
- 20.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.